实现公平的猴痘疫苗接种覆盖:短缺分析——美国,2022年5月至2023年4月
2022年猴痘疫情中美国接种首剂JYNNEOS疫苗748,329剂,短缺分析显示至2023年4月66.0%符合接种条件者仍未接种,非西班牙裔黑人或非裔美国人短缺最大(77.9%),其次为非西班牙裔美洲印第安人或阿拉斯加原住民(74.5%),需在黑人及AI/AN人群中大幅降低短缺以实现公平。
要点
- 2022年5月至2023年4月美国接种首剂JYNNEOS疫苗748,329剂,66.0%符合接种条件者仍未接种。
- 非西班牙裔黑人(77.9%)和非西班牙裔美洲印第安人/阿拉斯加原住民(74.5%)疫苗短缺最大。
- 8月和9月短缺降幅最大(17.7%和8.5%),但黑人同期降幅较小(12.2%和4.9%)。
核心结论
- 2022年5月至2023年4月美国所有种族和族裔群体的猴痘疫苗接种短缺均下降,但基于有种族和族裔报告的接种数据分析,期末仍有66.0%符合接种条件者未接种。
- 实现JYNNEOS疫苗接种覆盖的公平进展需要在黑人和AI/AN人群中大幅降低短缺。
研究设计与样本
- 对美国2022年5月至2023年4月猴痘疫苗接种数据开展短缺分析,短缺定义为符合接种条件人群中未接种首剂疫苗的百分比(即100%减去已接种首剂疫苗的符合条件人群百分比)。
主要发现
- 2022年5月至2023年4月美国共接种首剂JYNNEOS疫苗748,329剂(两剂推荐方案中的第一剂)。
- 期末非西班牙裔黑人短缺77.9%,非西班牙裔美洲印第安人或阿拉斯加原住民短缺74.5%,非西班牙裔白人短缺66.6%,西班牙裔或拉丁裔短缺63.0%,非西班牙裔亚裔短缺38.5%,非西班牙裔夏威夷原住民和其他太平洋岛民短缺43.7%。
- 短缺百分比降幅最大出现在8月(17.7%)和9月(8.5%),但同期黑人降幅较小(分别为12.2%和4.9%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More than 30,000 monkeypox (mpox) cases were reported in the United States during the 2022 multinational outbreak; cases disproportionately affected gay, bisexual, and other men who have sex with men (MSM). Substantial racial and ethnic disparities in incidence were also reported (1). The national mpox vaccination strategy* emphasizes that efforts to administer the JYNNEOS mpox vaccine should be focused among the populations at elevated risk for exposure to mpox (2). During May 2022-April 2023, a total of 748,329 first JYNNEOS vaccine doses (of the two recommended) were administered in the United States.† During the initial months of the outbreak, lower vaccination coverage rates among racial and ethnic minority groups were reported (1,3); however, after implementation of initiatives developed to expand access to mpox vaccination,§ coverage among racial and ethnic minority groups increased (1,4). A shortfall analysis was conducted to examine whether the increase in mpox vaccination coverage was equitable across all racial and ethnic groups (5). Shortfall was defined as the percentage of the vaccine-eligible population that did not receive the vaccine (i.e., 100% minus the percentage of the eligible population that did receive a first dose). Monthly mpox vaccination shortfalls were calculated and were stratified by race and ethnicity; monthly percent reductions in shortfall were also calculated compared with the preceding month's shortfall (6). The mpox vaccination shortfall decreased among all racial and ethnic groups during May 2022-April 2023; however, based on analysis of vaccine administration data with race and ethnicity reported, 66.0% of vaccine-eligible persons remained unvaccinated at the end of this period. The shortfall was largest among non-Hispanic Black or African American (Black) (77.9%) and non-Hispanic American Indian or Alaska Native (AI/AN) (74.5%) persons, followed by non-Hispanic White (White) (66.6%) and Hispanic or Latino (Hispanic) (63.0%) persons, and was lowest among non-Hispanic Asian (Asian) (38.5%) and non-Hispanic Native Hawaiian and other Pacific Islander (NH/OPI) (43.7%) persons. The largest percentage decreases in the shortfall were achieved during August (17.7%) and September (8.5%). However, during these months, smaller percentage decreases were achieved among Black persons (12.2% and 4.9%, respectively), highlighting the need for a focus on equity for the entirety of a public health response. Achieving equitable progress in JYNNEOS vaccination coverage will require substantial decreases in shortfalls among Black and AI/AN persons.
引用
- Kota KK, Chesson H, Hong J, et al. Progress Toward Equitable Mpox Vaccination Coverage: A Shortfall Analysis - United States, May 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37289660. doi:10.15585/mmwr.mm7223a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。